Clinical Trial

Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Lung cancer remains the world's leading cancer in terms of morbidity and mortality, with more than 20 million new cases and 9.7 million deaths annually. Despite improvements in surgical techniques and medical care, the number of elderly people undergoing surgery is gradually increasing, so there are an increasing number of complications following lung resection. Postoperative cerebral infarction is a relatively rare but devastating complication that places a heavy burden on patients and families. The incidence of postoperative cerebral infarction in patients after thoracic surgery has been reported to be 0.6-1.1%. There is a risk of postoperative cerebral infarction after lung cancer surgery, and the results of a few studies have shown that postoperative cerebral infarction is related to old age, male, hypertension, hyperlipidemia, and lobectomy factors, but the pathogenesis of the occurrence of cerebral infarction has not been clearly proved for the time being, and so these risk factors cannot be taken as the direct cause of cerebral infarction. Therefore, we need to further explore the factors leading to cerebral infarction after lung cancer surgery. If we can further prove that some of the risk factors are related to the causes of cerebral infarction after lung cancer surgery, we can make corresponding strategies in the perioperative period to improve the safety of surgery and reduce the incidence of cerebral infarction in the postoperative period.
Trial Details
NCT Number NCT06942845
Lead Sponsor Xinghua Cheng
Conditions Lung Cancer, Non-Small Cell, Postoperative Cerebral Infarction
Enrollment 300 participants
Start Date 2025-04-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-24